Aquaporin‐4 and caveolin‐1 as mediators of fibrinogen‐driven cerebrovascular pathology in cerebral amyloid angiopathy
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Vishal Singh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Physiology and Neurosciences, Rutgers-New Jersey Medical School, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Caveolin 1, Cerebral Amyloid Angiopathy, Aquaporin 4, Fibrinogen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
INTRODUCTION Cerebral amyloid angiopathy (CAA), marked by amyloid beta (Aβ) accumulation in perivascular spaces (PVSs), contributes to vascular injury and inflammation in Alzheimer's disease. The mechanisms underlying CAA‐related vascular pathology remain unclear. Increasing evidence indicates fibrinogen, the main component in blood clots, interacts with Aβ and exacerbates inflammation and co‐deposits in PVS of CAA‐positive vessels, yet its role in cerebrovascular dysfunction remains poorly defined. METHODS Using TgSwDI transgenic mice, which develop robust CAA, we examined fibrin(ogen) deposition, aquaporin‐4 (AQP4) polarization, and caveolin‐1 (Cav‐1) expression. We further assessed the effects of fibrinogen depletion via small interfering RNA. RESULTS TgSwDI mice showed increased fibrin(ogen) extravasation, colocalization with Aβ in PVS, AQP4 depolarization, and elevated Cav‐1 expression. Fibrinogen depletion reduced CAA, restored AQP4 polarization, decreased Cav‐1 levels, attenuated microglial activation, and improved spatial memory. DISCUSSION These findings suggest that modulating fibrinogen‐related pathways could be a promising strategy for mitigating CAA pathology and its associated cerebrovascular pathology. Highlights Fibrin(ogen)‐Aβ colocalization aggravates CAA. AQP4 depolarization links fibrinogen‐Aβ deposits to impaired clearance in CAA. Cav‐1 increase drives fibrinogen leakage and neuroinflammation. Fibrinogen depletion reduces CAA, restores AQP4 polarity, and improves memory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Physiology and Neurosciences, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.
- Versiti Blood Research Institute, Milwaukee, Wisconsin, USA.
- Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.
- Departments of Surgery, Biochemistry, Biomedical Engineering, and Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Brain Health Institute, Rutgers University, Piscataway, New Jersey, USA.
ORCID-Profile: Hyung Jin Ahn
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- NIH HHS
- NHLBI NIH HHS
- National Institutes of Health
Zitieren
APA
Singh, V., Rochakim, N., Ferraresso, F., Garg, K., Rizvi, A. B., Choudhury, A., Kastrup, C. J., & Ahn, H. J. (2026). Aquaporin‐4 and caveolin‐1 as mediators of fibrinogen‐driven cerebrovascular pathology in cerebral amyloid angiopathy. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71030
Vancouver
Singh V, Rochakim N, Ferraresso F, Garg K, Rizvi AB, Choudhury A, et al. Aquaporin‐4 and caveolin‐1 as mediators of fibrinogen‐driven cerebrovascular pathology in cerebral amyloid angiopathy. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71030
BibTeX
@article{Singh2026,
author = {Singh, Vishal and Rochakim, Nicholas and Ferraresso, Francesca and Garg, Khushi and Rizvi, Asma B and Choudhury, Arnab and Kastrup, Christian J and Ahn, Hyung Jin},
title = {Aquaporin‐4 and caveolin‐1 as mediators of fibrinogen‐driven cerebrovascular pathology in cerebral amyloid angiopathy},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71030}
}
EUVIMED